Should I buy Lam Research (LRCX) stock or is it too late?
⭐ The most reliable of them, either direction: B. Riley Securities — 72% of its targets hit on this sector (170 calls tested). It aims for $350 (+9.9 %), call made on July 31, 2026, maturing on July 31, 2027 (28 d ago).
Firm-by-firm track record on Lam Research
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Cantor Fitzgerald | 100 % | +221.0 % | 6 | $500 +57% |
| Needham | 81 % | +90.4 % | 16 | $390 +22% |
| Mizuho | 75 % | +77.2 % | 24 | $365 +15% |
| Goldman Sachs | 73 % | +72.5 % | 11 | $262 -18% |
| B. Riley Securities | 80 % | +71.1 % | 20 | $350 +10% |
| B of A Securities | 73 % | +69.0 % | 11 | $480 +51% |
| Stifel | 78 % | +61.6 % | 23 | $425 +33% |
| UBS | 71 % | +59.3 % | 17 | $375 +18% |
✅ Reasons to believe
- 95% of analysts rate it a buy (Buy consensus, 19 ratings) — a sign of market conviction.
- Median price target $367, i.e. +15% from the current price ($319).
- The most reliable firm on LRCX, Oppenheimer (100% hit rate, 4 scored calls), targets $400 (call made on June 15, 2026, maturing on June 15, 2027) (+26%) in its most recent call.
- 15 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 19 ratings, 1 is neutral.
- High valuation (P/E ~54): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Volatile stock: sharp swings — including steep drops — are part of its profile.
- Negligible dividend (0.3% yield): your return depends mostly on price appreciation.
The analyst consensus on LRCX
Median target $367 (+15%) · 19 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Lam Research now?
We won't decide for you. The facts: 95% of analysts rate it a buy, median target $367 (+15%), and Oppenheimer (most reliable on LRCX, 100%) targets $400. Weigh that against valuation (P/E ~54) and volatility. This is not personalized advice.
Is it too late to invest in Lam Research?
Not according to analysts: the median target ($367) is still +15% above the current price ($319) (most reliable on LRCX: Oppenheimer, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Lam Research still worth investing in?
It depends on the gap between the price ($319) and its estimated value: analysts target $367 on median (+15%), with 95% buys (most reliable on LRCX: Oppenheimer, 100%). Cross-check with their real reliability on LRCX and the cautions above. Information, not advice.
What's the main risk in buying LRCX?
The consensus is not unanimous: of 19 ratings, 1 is neutral.
→ Go deeper: the full Lam Research profile (consensus, analyst reliability, price target, performance).